Preliminary unaudited full year 2023 net revenue is expected to be $148.7 million, representing growth of 22% compared to $122.3 million in 2022. Preliminary full year domestic net revenue is expected to be $111.0 million, representing 20% annual growth and international net revenue is expected to be $37.7 million, representing 26% annual growth. “Despite historically high rates of respiratory illness in the back half of the fourth quarter, we produced strong revenue growth of 21%, reflecting continued commercial and operational execution,” commented David Bailey, President & CEO of OrthoPediatrics. “OrthoPediatrics remains in its strongest strategic position of all time, supported by an expanding user base, robust product portfolio, recent acquisitions, and a growing international presence.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on KIDS:
- OrthoPediatrics Corp. Announces Preliminary Unaudited Financial Highlights for the Fourth Quarter & Full Year 2023
- OrthoPediatrics Corp. Announces Acquisition of Boston Orthotics & Prosthetics
- OrthoPediatrics price target raised to $39 from $35 at Truist
- OrthoPediatrics price target lowered to $50 from $60 at JMP Securities
- OrthoPediatrics announces launch of specialty bracing division